FDA Calls GlaxoSmithKline Professional Mailers For Tykerb “Misleading”
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK shares FDA’s concerns, but says the promos were accompanied by full prescribing information, firm tells “The Pink Sheet” DAILY.